Three are coronavirus vaccines already in phase 3 of clinical trials: the American Modern, the British in which the pharmaceutical company collaborates AstraZeneca and the University of Oxford, and the China.
Given this, there are already several countries that have already begun to close their purchases, given the exponential increase in cases, which this Thursday has reached its daily record of infections, with 289,100 positive cases in the last 24 hours.
United States, United Kingdom, Brazil and China These are the countries that have their coronavirus vaccine stocks assured. Between the four they have acquired hundreds of thousands doses, a purchase that has been left out of Europe, which has prevented member countries from negotiating separately.
The premise of the block is not to acquire or negotiate if there is no conclusive evidence that the vaccine is effective and safe. So, Europe is left out of the massive purchase of this injectable, for which countries such as the Netherlands, Germany, Italy and France, those belonging to the Inclusive Vaccine Alliance, have already negotiated.
It was last June when the British pharmacist AstraZeneca announced that it has signed a 400 million doses with several member states of the European Union to supply them with their potential coronavirus vaccine. Given this, Brussels forced them to step on the brake and announced that there would be a centralized purchase only until the vaccine proves effective.
USA: 100 million
Pharmaceuticals Pfizer and BioNTech have reached a agreement with the United States Government to sell you 100 million doses of BNT162, its candidate for vaccine against Covid-19, for 1,950 million dollars (1,684 million euros).
Once the vaccine receives the go-ahead from the United States Food and Drug Administration (FDA), Washington will pay the 1.95 billion dollars, although it reserves the right to purchase another 500 million doses if it deems it necessary.
United Kingdom: 60 million
This Wednesday, the British Government has reached an agreement to purchase 60 million doses of a new coronavirus vaccine developed by the pharmaceutical companies Sanofi and GSK.
This contract, which is pending approval, will supply the government with 60 million doses of this new vaccine if it is able to prove its efficacy in the tests to be carried out in September.
The Minister of Science and Innovation, Pedro Duque, has affirmed this Thursday that he is “much more optimistic” than three or four weeks ago about the availability of the Spanish prototypes of the vaccine against Covid-19, and considered “quite possible” that Vaccine tests are carried out in Spain “shortly”, possibly before the end of the year.
These statements come after it was learned that some of the Spanish prototypes of the vaccine are now immersed in animal experiments and, if the results are positive, several groups could ask the Spanish Medicines Agency in December for permission to start the human clinical trials.
Once this permission was obtained, which could take weeks or months, the first phase of these trials with healthy volunteers would begin.